Tag: INSY

Blue Horseshoe Stocks: WATT Recap & More

Energous Corp. WATT

On our premarket watchlists for both Wednesday and yesterday morning, has been WATT, which received some exciting news this week.

The company revealed that the FCC has granted consumer safety certification for its wireless charging technology, marking the first FCC approval for remote wireless charging, and opening the door to commercialization.

Its applications are plentiful, and the potential is high, and it’s showing on the chart. On Wednesday morning following our alert, the stock was trading for as little as 15.30, and at its high of day yesterday, the stock had reached 33.50. That represented a two-session swing of 119% as it set new all-time highs for volume two days in a row.

We will be very interested to continue tracking the story behind this huge turn of events for WATT.

Helios and Matheson Analytics, Inc. HMNY

We also would like to recap HMNY’s performance yesterday. We tagged this one as a bottom play and ended up timing the bounce with absolute precision.

The stock had been in an overall downtrend since the end of November, and yesterday, began what could be just the start of a more sustained recovery.

HMNY traded up from a low of 5.45 and went on to reach a high of 6.98, for a modest but respectable increase of 28% on the day. It happened on roughly three times the monthly average volume, and closed near the high of day, so we’ll definitely be on the lookout for momentum carryover.


INSYS Therapeutics, Inc. INSY

Just a quick reminder about the options idea we had for INSY recently. We already reported the solid gains we’ve witnessed in the INSY 01/19 $8 and $9 Calls on Wednesday morning, but given the current conditions on the chart, we’ll want to keep an eye peeled for further bullish activity in those contracts.

Extended Watchlist:
ADHC, AGTK, CATB, GENE, PGNX, PGLC, SMIT,

Blue Horseshoe Stocks: TEUM Update & More

Pareteum Corp. TEUM

The last time we mentioned TEUM was December 8th, shortly after which time the stock was trading for as little as .661. At the time the company had no involvement in the trendy cryptocurrency space.

Flash forward to this week, and an announcement that the company is adding blockchain capability for cryptocurrency support on its global cloud billing platform has the stock soaring to new highs.

TEUM hit 3.15 yesterday, which marks an increase of 377% in less than three weeks’ time. Volume for the day was on the order of roughly five times the monthly average.

Bitcoin itself has been making a nice rebound after the pullback which followed its big run to nearly $20K, and there is no reason to suspect that the push toward blockchain related technologies, both cryptocurrency and otherwise, is just a passing fad.

INSYS Therapeutics, Inc. INSY – Options Recap

We made our interest in the INSY 01/19 $8 & $9 Calls known yesterday morning, and it barely took any time at all for our ideas to come to fruition.

As we were mentioning yesterday, the company recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy, and the FDA granted Fast Track status to the ‘drug’ for the treatment of a rare genetic disorder (Prader-Willi).

This news allowed for some very nice moves in our designated contracts. The $8 Calls ran from .35-1.00 for a gain of 186%, while the $9’s traded up from .20-.55, trending up 175% on the day.

Ampio Pharmaceuticals, Inc. AMPE

We also want to swing back to remind our readers of last week’s alert on AMPE. We tagged this play seven days ago (four trading days), and saw it trading for as little as 2.57. As of yesterday’s high of 3.55, the stock had thus far risen by 38%

The stock’s peak PPS represented a new annual high, so we’ll be interested to see how the stock performs in blue skies.

Extended Watchlist:
OTIV, FH, NETE, LFIN, GROW, IDXG, WATT, ATNM

Blue Horseshoe Stocks: Kicking Off the Short Week

INSYS Therapeutics, Inc. INSY

This morning we kick off the holiday shortened week, during a time of year that typically sees subdued activity for the markets as a whole, as people spend time with their families, and stay busy with holiday festivities.

We still strive to identify possible opportunities even in this environment, and the first thing to hit our scanner this morning was INSY. INSYS Therapeutics recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy.

The FDA, we’re learning today, has also granted Fast Track status to INSY for the ‘drug’ for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder. (View PR)

The stock registered its 52-week lows at the beginning of last month, and has been in a general uptrend since, but we’ll be looking for further bullish activity on the heels of this FDA news, both on the stock chart, and in the options chain as a secondary idea. For that, we’ll look to the INSY 01/19 $8 & $9 Calls for opportunities.

DelMar Pharmaceuticals, Inc. DMPI

Speaking of FDA Fast Track designations, we’re looking to DMPI this morning as well, which was granted the status by the FDA for its lead-product cancer treatment, VAL-083.

The chart itself was already set up as a possible bottom play, and despite gapping up considerably on this morning’s news, there is still room to the upside, including a sizable gap that’s been left on the chart since this past spring, the eventual filling of which would spell gains of more than 100% from the current PPS.

Extended Watchlist:
KLXI, EXXI, AEZS, SRAX, IMUC, NETE